Cargando…

Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies

Detalles Bibliográficos
Autores principales:	Petzer, Verena, Steiner, Normann, Angelova-Unterberger, Olga, Hetzenauer, Gabriele, Philipp-Abbrederis, Kathrin, Willenbacher, Ella, Feistritzer, Clemens, Willenbacher, Wolfgang, Rudzki, Jakob, Stauder, Reinhard, Kocher, Florian, Seeber, Andreas, Pircher, Andreas, Tymoszuk, Piotr, Irsara, Christian, Egger, Alexander, Fux, Vilmos, Anliker, Markus, Gunsilius, Eberhard, Nachbaur, David, Schmidt, Stefan, Wolf, Dominik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849383/ https://www.ncbi.nlm.nih.gov/pubmed/35187405 http://dx.doi.org/10.1097/HS9.0000000000000686

Ejemplares similares

Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study
por: Steiner, Normann, et al.
Publicado: (2023)

Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma—A case report
por: Gauckler, Philipp, et al.
Publicado: (2020)

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies
por: Willenbacher, Wolfgang, et al.
Publicado: (2018)

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project
por: Seeber, Andreas, et al.
Publicado: (2016)

Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL)
por: Künz, Tina, et al.
Publicado: (2022)

The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond
por: Strassl, Irene, et al.
Publicado: (2021)

The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo
por: Borjan, Bojana, et al.
Publicado: (2015)

Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017)

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event
por: Locher, Maurus, et al.
Publicado: (2020)

Early autologous and allogeneic peripheral blood stem cell transplantation for adult patients with acute B and T cell precursor neoplasms: a 12-year single center experience
por: Steiner, Normann, et al.
Publicado: (2021)

Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma
por: Locher, Maurus, et al.
Publicado: (2022)

Marine compounds inhibit growth of multiple myeloma in vitro and in vivo
por: Steiner, Normann, et al.
Publicado: (2015)

Curcumin: New Insights into an Ancient Ingredient against Cancer
por: Willenbacher, Ella, et al.
Publicado: (2019)

Erratum: Willenbacher, E., et al. Curcumin: New Insights into an Ancient Ingredient against Cancer. Int. J. Mol. Sci. 2019, 20, 1808
por: Willenbacher, Ella, et al.
Publicado: (2020)

ASCO 2018 NSCLC highlights—combination therapy is key
por: Gamerith, Gabriele, et al.
Publicado: (2018)

The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets
por: Steiner, Normann, et al.
Publicado: (2018)

Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies
por: Pircher, Andreas, et al.
Publicado: (2016)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
por: Willenbacher, Ella, et al.
Publicado: (2018)

Classical and intermediate monocytes scavenge non-transferrin-bound iron and damaged erythrocytes
por: Haschka, David, et al.
Publicado: (2019)

The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent
por: Kocher, Florian, et al.
Publicado: (2020)

The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
por: Steiner, Normann, et al.
Publicado: (2020)

Disseminated focal (18)F-fluoro-deoxyglucose uptake upon granulocyte colony-stimulating factor therapy mimicking malignant bone infiltration: case report of a patient with very severe aplastic anemia
por: Horvath, Lena, et al.
Publicado: (2020)

Case report: successful perioperative management of patients with haemophilia A using an extended half-life factor VIII (Efmoroctocog alfa) during neurosurgical procedures
por: Kocher, Florian, et al.
Publicado: (2021)

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics
por: Willenbacher, Ella, et al.
Publicado: (2016)

Creating the “new normal” post-Coronavirus world—web-communication replacing face-to-face interaction
por: Hilbe, Wolfgang, et al.
Publicado: (2020)

Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury
por: Steiner, N., et al.
Publicado: (2020)

Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas
por: Willenbacher, Ella, et al.
Publicado: (2020)

Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia
por: Willenbacher, Ella, et al.
Publicado: (2019)

Challenges in Rheological Characterization of Highly Concentrated Suspensions — A Case Study for Screen-printing Silver Pastes
por: Yüce, Ceren, et al.
Publicado: (2017)

Death of unknown cause? Post-mortem diagnosis of fulminant course of an EBV-associated secondary hemophagocytic lymphohistiocytosis
por: Fauser, Josia, et al.
Publicado: (2021)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma
por: Thangavadivel, Shanmugapriya, et al.
Publicado: (2016)

Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature
por: Pircher, Andreas, et al.
Publicado: (2019)

Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia‐variant
por: Locher, Maurus, et al.
Publicado: (2020)

Highly conductive, printable pastes from capillary suspensions
por: Schneider, Monica, et al.
Publicado: (2016)

Effect of Polymeric Binders on Dispersion of Active Particles in Aqueous LiFePO(4)-Based Cathode Slurries as well as on Mechanical and Electrical Properties of Corresponding Dry Layers
por: Gordon, Ronald, et al.
Publicado: (2020)

Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer
por: Lanser, Lukas, et al.
Publicado: (2020)

Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients
por: Steiner, Normann, et al.
Publicado: (2017)

Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?
por: Steiner, Normann, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f60l57h3gmv235lqof6uvohgh7